New Amgen Scholars Web site Launches to Build a Global Network for Future Scientists

Amgen Inc.Each year, hundreds of undergraduate students from across the United States (U.S.) and Europe participate in the Amgen Scholars Program to gain hands-on laboratory experience under renowned faculty members at the world's leading universities. Now, the Amgen Scholars - past, present and future - will have exclusive access to the online Amgen Scholars Community.

"The new Web site is designed to connect, engage and inspire Amgen Scholars on a global level by bringing together participants from diverse backgrounds and wide-ranging scientific career aspirations," said Jean J. Lim, president of the Amgen Foundation. "We hope that the online community will enrich the experience for all Amgen Scholars, not only during the program, but throughout their future careers in science."

The new Web site, launched in partnership with The Scientist, a leading life sciences magazine, allows current Amgen Scholars and alumni to login and access tools aimed at helping them build professional networks and read the latest science and career news. Through the use of interactive polls, message boards, personal profiles and blogs, users can discuss their participation in the program and various science-related topics such as graduate education and career paths in research. Others interested in the program can also view past participant and faculty mentor profiles and read excerpts of student blogs from the online community in the publicly-accessible section of the site.

2010 Amgen Scholars Program Applications Now Available
Established in 2006, Amgen Scholars is a $27.5 million initiative that provides undergraduates with the opportunity for hands-on research at some of the world's leading institutions. The opportunity to work with top academic scientists is a cornerstone of the program, with participating universities seeking to match students with faculty members who will both inspire and challenge them. In addition, the U.S. and Europe programs each host a three-day symposium allowing students to share their summer research projects and hear firsthand from leading industry and academic scientists.

To date, more than 800 undergraduates have participated in the Amgen Scholars Program. Considered among the most competitive summer research programs in the U.S., several Amgen Scholar alumni have gone on to pursue doctorates at leading universities with some being selected for premier fellowships including the Rhodes Scholarships.

In the U.S., the host universities are California Institute of Technology; Columbia University/Barnard College; Howard University; MIT; Stanford University; University of California, Berkeley; UCLA; University of California, San Diego; University of California, San Francisco; and University of Washington. In Europe, the participating universities are the University of Cambridge; Karolinska Institute; and Ludwig-Maximilians-University.

Financial support for students is a critical component of the U.S. and Europe programs, which aims to ensure that eligible students, regardless of their financial status, are able to participate. Please note that details vary by host university.

For more information about Amgen Scholars including eligibility criteria and applications, please visit www.amgenscholars.com.

About the Amgen Foundation
The Amgen Foundation (www.amgen.com/citizenship/overview.html) seeks to advance science education; improve patient access to quality care; and strengthen the communities where Amgen staff members live and work. Since 1991, the Foundation has made $130 million in grants to nonprofit organizations throughout the United States, Puerto Rico and Europe that impact society in inspiring and innovative ways, and those that provide disaster relief efforts internationally.

Most Popular Now

Cannabis extract helps reset brain function in psy…

Research from King's College London has found that a single dose of the cannabis extract cannabidiol can help reduce brain function abnormalities seen in people with psyc...

For first time in 40 years, cure for acute leukemi…

Acute myeloid leukemia is one of the most aggressive cancers. While other cancers have benefitted from new treatments, there has been no encouraging news for most leukemi...

New cancer treatment uses enzymes to boost immune …

Researchers at The University of Texas at Austin have developed a new approach to treating cancer using enzyme therapy. The enzyme, PEG-KYNase, does not directly kill can...

Bayer accelerates six new startups

Changing the experience of health: that's the focus of the six startups which the Bayer G4A team has included in the Accelerator program this year. The young companies fr...

Novartis receives European Commission approval of …

Novartis today announced that the European Commission (EC) has approved Kymriah® (tisagenlecleucel, formerly CTL019). The approved indications are for the treatment of pe...

Shire completes sale of oncology franchise

Shire plc (LSE: SHP, NASDAQ: SHPG) announces today that it has completed the sale of its Oncology franchise to Servier S.A.S. for $2.4 billion. The franchise includes the...

Antioxidant reduces risk for second heart attack, …

Doctors have long known that in the months after a heart attack or stroke, patients are more likely to have another attack or stroke. Now, a paper in the Journal of the A...

Novartis to divest the Sandoz US dermatology busin…

Novartis today announced it has agreed to sell selected portions of its Sandoz US portfolio, specifically the Sandoz US dermatology business and generic US oral solids po...

New tablet production facility in Ingelheim: Cente…

Boehringer Ingelheim held a groundbreaking ceremony for the construction of a new production facility for innovative drugs. This new Solids Launch facility will focus on ...

SOLAR-1 trial of Novartis investigational alpha-sp…

Novartis today announced the global Phase III SOLAR-1 trial evaluating the investigational alpha-specific PI3K inhibitor BYL719 (alpelisib) has met the primary endpoint s...

Tezepelumab granted Breakthrough Therapy Designati…

AstraZeneca and its partner Amgen Inc. (Amgen) today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for tezepelumab...

Pfizer terminates domagrozumab (PF-06252616) clini…

Pfizer Inc. (NYSE: PFE) announced that it is terminating two ongoing clinical studies evaluating domagrozumab (PF-06252616) for the treatment of Duchenne muscular dystrop...